DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTOR
DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTOR
批准号:
3337739
负责人:
GUY C LEBRETON
金额:
$23.91万
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-09-30 至 1992-09-29
关键词:
arachidonate chromatography dogs drug design /synthesis /production drug metabolism drug quality /standard gel electrophoresis inhibitor /antagonist membrane activity nuclear magnetic resonance spectroscopy platelet activation platelet aggregation inhibitors platelets prostaglandins radioimmunoassay receptor thromboxanes
中文摘要
我们以前报道了一个合成和药理活性的
一系列直接抑制人血小板的新化合物
血栓素A2/前列腺素H2(TXA2/PGH2)受体。 结果发现
这些试剂,特别是13-氮杂前列腺烷酸(13-APA)2,
拮抗TXA_2/PGH_2诱导的血小板活化,
对其他生理激动剂诱导的血小板活化的影响。 在
目前的建议,研究已经设计,现在使用这些代理人
作为研究潜在机制的选择性药理学工具
与TXA2/PGH2诱导的血小板活化有关。 具体地说,
实验提出进行结合研究,使用(3H)13-APA在
完整血小板和血小板膜制品。 这些研究应
提供第一个直接证据,证明存在和位置,
血小板TXA2/PGH2受体。 为了识别和表征
这种假定受体的蛋白质组成,放射性标记的烷化剂
将使用13-APA的衍生物。 此外,实验
建议更清楚地建立TXA2和PGH2的相对能力,
引起血小板活化。 通过使用竞争性受体
结合试验在这个建议和选择性TXA2合成酶
抑制剂,应该有可能确定PGH2是否是
自身能够与血小板受体相互作用。 最后我们将
探讨直接TXA2/PGH2受体拮抗剂单独或
联合前列环素可以作为一种有效的手段,
降低体内血小板反应性。 除上述研究外,
将进行综合规划,以开发新药剂,
在进一步表征TXA2/PGH2的参与方面具有重要价值
血小板活化 该计划将涉及新的合成
化合物,以研究与
TXA2/PGH2受体,以及合成修饰的
13-azaprostanoid(用于亲和层析)以纯化受体
绝佳的价钱 因此,这一建议的广度从分子水平延伸到了分子水平。
TXA_2与其受体的相互作用在
血栓素A2拮抗剂在体内抑制血小板活化。 这
为今后的发展提供更合理的基础。
用于治疗血栓栓塞性疾病的药物。
英文摘要
We previously reported the synthesis and pharmacological activity of a
series of new compounds which directly inhibit the human blood platelet
thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor. It was found that
these agents, in particular 13-azaprostanoic acid (13-APA)2, specifically
antagonize platelet activation induced by TXA2/PGH2, with virtually no
effects on platelet activation induced by other physiological agonists. In
the present proposal, studies have been designed to now employ these agents
as selective pharmacological tools to investigate the underlying mechanism
associated with TXA2/PGH2-induced platelet activation. Specifically,
experiments are proposed to perform binding studies using (3H) 13-APA in
intact platelets and platelet membrane preparations. These studies should
provide the first direct evidence for the existence and location of a
platelet TXA2/PGH2 receptor. In order to identify and characterize the
protein composition of this presumed receptor, a radiolabeled alkylating
derivative of 13-APA will be employed. In addition, experiments are
proposed to more clearly establish the relative ability of TXA2 and PGH2 to
cause platelet activation. Through the use of a competitive receptor
binding assay developed in this proposal and selective TXA2 synthetase
inhibitors, it should be possible to establish whether or not PGH2 is
itself capable of interacting with a platelet receptor. Finally, we will
explore the possibility that direct TXA2/PGH2 receptor antagonism alone or
in combination with prostacyclin may serve as an effective means of
reducing platelet reactivity in vivo. In addition to the above studies a
synthetic program will be undertaken to develop new agents which should be
of substantial value in further characterizing the involvement of TXA2/PGH2
in platelet activation. This program will involve the synthesis of new
compounds to investigate the structural requirements for interaction with
the TXA2/PGH2 receptor, as well as the synthesis of a modified
13-azaprostanoid (for affinity chromatography) to purify the receptor
site. The breadth of this proposal therefore extends from the molecular
interaction of TXA2 with its receptor to the application of
TXA2-antagonists to the inhibition of platelet activation in vivo. This
approach should provide a more rational basis for the future development of
pharmacological agents useful in the treatment of thromboembolic disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:2906502
-
项目类别:
-
资助金额:$27.21万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTOR
-
批准号:3337737
-
项目类别:
-
资助金额:$23.57万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTOR
-
批准号:3337730
-
项目类别:
-
资助金额:$24.83万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:2609203
-
项目类别:
-
资助金额:$28.0万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:6183587
-
项目类别:
-
资助金额:$27.28万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:6536788
-
项目类别:
-
资助金额:$28.73万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:6388858
-
项目类别:
-
资助金额:$28.09万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:7166091
-
项目类别:
-
资助金额:$32.54万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:7800286
-
项目类别:
-
资助金额:$39.25万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:8446365
-
项目类别:
-
资助金额:$36.99万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:6836442
-
项目类别:
-
资助金额:$34.32万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:6999378
-
项目类别:
-
资助金额:$33.51万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTOR
-
批准号:3337738
-
项目类别:
-
资助金额:$23.78万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:2028052
-
项目类别:
-
资助金额:$26.8万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:6731588
-
项目类别:
-
资助金额:$34.32万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:2215769
-
项目类别:
-
资助金额:$24.92万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
BLOOD PLATELET THROMBOXANE RECEPTORS
-
批准号:2215770
-
项目类别:
-
资助金额:$25.75万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:8046429
-
项目类别:
-
资助金额:$39.25万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
Blood Platelet Thromboxane Receptors
-
批准号:8244415
-
项目类别:
-
资助金额:$38.86万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
DIRECT ANTAGONISM OF THE TXA2 BLOOD PLATELET RECEPTOR
-
批准号:3337736
-
项目类别:
-
资助金额:$23.23万
-
财政年份:1987
-
负责人:GUY C LEBRETON
-
依托单位:
海外基金